Intra-Cellular Therapies, Inc. (ITCI) |
|
54.09 0.87 (1.63%)
|
12-07 16:00 |
|
Open: |
52.9 |
Pre. Close: |
53.22 |
|
High:
|
54.98 |
Low:
|
52.9 |
|
Volume:
|
615,196 |
Market Cap:
|
5,123(M) |
|
|
|
Technical analysis |
as of: 2022-12-07 4:23:19 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 64.21  One year: 75 |
| Support: |
Support1: 48.1 Support2: 43.85 |
| Resistance: |
Resistance1: 54.97 Resistance2: 64.21 |
| Pivot: |
52.61 |
| Moving Average: |
MA(5): 53.81  MA(20): 52.22
MA(100): 50.58 MA(250): 52.58 |
| MACD: |
MACD(12,26): 1.3 Signal(9): 1.2 |
| Stochastic oscillator: |
%K(14,3): 82.5 %D(3): 83.4 |
| RSI: |
RSI(14): 59.7 |
| 52-week: |
High: 66 Low: 34.88 |
| Average Vol(K): |
3-Month: 691 (K) 10-Days: 453 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ITCI ] has closed below upper band by 21.5%. Bollinger Bands are 33.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
55.02 - 55.28 |
55.28 - 55.53 |
|
Low:
|
52.24 - 52.54 |
52.54 - 52.82 |
|
Close:
|
53.6 - 54.07 |
54.07 - 54.51 |
|
Company Description |
|
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York. |
Headline News |
Wed, 07 Dec 2022
Stock Market Extends Losses As Corporate Earnings Not Enough To Allay Investor Concerns - Investor's Business Daily
Fri, 02 Dec 2022
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) EVP Sells $2686500.00 in Stock - MarketBeat
Wed, 30 Nov 2022
Is DICE Therapeutics (DICE) Outperforming Other Medical Stocks This Year? - Nasdaq
Sat, 26 Nov 2022
Is Intra-Cellular Therapies (ITCI) Stock a Worthy Buy? - Yahoo Finance
Fri, 18 Nov 2022
Intra-Cellular's (ITCI) Caplyta Aids Growth, Overdependence a Woe - Zacks Investment Research
Fri, 11 Nov 2022
Have Insiders Sold Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Recently? - Simply Wall St
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. |
95 (M) |
| Shares Float |
88 (M) |
|
% Held by Insiders
|
2.6 (%) |
|
% Held by Institutions
|
94.4 (%) |
|
Shares Short
|
4,060 (K) |
|
Shares Short P.Month
|
4,080 (K) |
Stock Financials |
|
EPS
|
-3.61 |
|
EPS Est Next Qtl
|
-0.69 |
|
EPS Est This Year
|
-2.34 |
|
EPS Est Next Year
|
-2.81 |
|
Book Value (p.s.)
|
7.23 |
|
Profit Margin (%)
|
-158.4 |
|
Operating Margin (%)
|
-160.7 |
|
Return on Assets (ttm)
|
-28.3 |
|
Return on Equity (ttm)
|
-50.9 |
|
Qtrly Rev. Growth
|
223.6 |
|
Gross Profit (p.s.)
|
-0.14 |
|
Sales Per Share
|
1.98 |
|
EBITDA (p.s.)
|
-3.19 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-304 (M) |
|
Levered Free Cash Flow
|
-196 (M) |
Stock Valuations |
|
PE Ratio
|
-14.99 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
7.47 |
|
Price to Sales
|
27.23 |
|
Price to Cash Flow
|
-16.85 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
